Clinical evidence, encompassing trials, epidemiological investigations, and findings from animal toxicology and histological studies, has revealed potential associations between GLP-1RAs and the risk of neuroendocrine tumors and exocrine pancreatic dysplasia, with some evidence suggesting an increased risk of pancreatic cancer [6]
however, it is important to note that glucagon receptor activation also stimulates hepatic glucose production, and the net metabolic effect of this component in humans is still being characterised
What Is an Evidence Based GLP 1 Weight Loss Program
Always follow your healthcare providers instructions for best results
Bringing together virtual care and our physical pharmacy network is central to how were approaching the future of health and wellness, creating a more connected experience that helps simplify the journey for customers every day
Dora Matis - April 13, 2026 GLP-1 receptor agonists such as semaglutide-based medications support blood sugar control, weight loss, and cardiovascular health through effects on insulin, appetite, and gastric emptying